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Purpose
Early detection of lymph node (LN) metastases using PSMA-PET has renewed interest in radical treatment of men with newly diagnosed LN-positive prostate cancer. Several guidelines suggest dose-escalated IMRT (DE-IMRT) to the prostate and pelvic LNs as a preferred alternative to systemic therapy alone 1 . However there are few reports using high boost doses guided by PSMA-PET. We aimed to evaluate our experience using this approach.
Methods and materials
All patients with newly diagnosed high-risk prostate cancer were staged using PSMA-PET, CT and bone scans. Patients with LN only metastases were offered curative-intent therapy using 3 months of neoadjuvant androgen deprivation therapy (ADT) followed by DE-IMRT, followed by 3 years of ADT. IMRT was delivered using VMAT. All patients had fiducial marker insertion. Privately-insured patients had spacer hydrogel insertion. PSMA-PET and prostate MRI were fused with the planning CT. Our protocol aimed to deliver 81Gy to the prostate and PET-positive LNs and 60Gy to the bilateral elective pelvic lymph nodes in 45 fractions.
Results
46 patients were treated. Median age was 70 years (range 51-81), median PSA 13 µg/L (range 1.33-190), 67% were T3 or T4, 83% were Gleason 8-10, median number of LNs was 2 (range 1-6), and median PET positive LN volume was 1.14cc (range 0.15-4.14). LNs were outside of standard contouring guidelines in 17 patients (37.0%). For 4 patients, dose to PET-positive LNs was limited to 72-74Gy to meet small bowel constraints.
With median follow up of 24 months (range 10-50), 2-year failure-free survival was 100%, and 2-year overall survival 95.7%. One patient had PSA failure at 30 months and distant failure at 31 months, with PET showing no prostate or LN avid disease. One patient died of myeloma at 24 months.
Acute and late toxicity data is illustrated in tables 1 and 2 below. The grade 3 toxicities were bulbar stricture requiring dilatation (1 patient), and TURP (1 patient). No toxicity was attributable to the high dose LN boost. 
Conclusion
PSMA-PET guided DE-IMRT up to 81Gy to the prostate and involved LNs, and longterm ADT, is a promising approach for newly diagnosed node positive prostate cancer, with excellent 2-year toxicity and efficacy outcomes. Lymph node contouring guidelines require re-evaluation in the PSMA-PET era.
